{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:30:58Z","timestamp":1791307858131,"version":"4.3.1"},"reference-count":170,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,9,3]],"date-time":"2013-09-03T00:00:00Z","timestamp":1378166400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1038\/nrclinonc.2013.158","type":"journal-article","created":{"date-parts":[[2013,9,3]],"date-time":"2013-09-03T11:26:32Z","timestamp":1378207592000},"page":"571-587","source":"Crossref","is-referenced-by-count":264,"title":["Drug rechallenge and treatment beyond progression\u2014implications for drug resistance"],"prefix":"10.1038","volume":"10","author":[{"given":"Elizabeth A.","family":"Kuczynski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Sargent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Grothey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Kerbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,9,3]]},"reference":[{"key":"BFnrclinonc2013158_CR1","first-page":"1727","volume":"63","author":"JH Goldie","year":"1979","unstructured":"Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63, 1727\u20131733 (1979).","journal-title":"Cancer Treat. Rep."},{"key":"BFnrclinonc2013158_CR2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nature10762","volume":"481","author":"M Greaves","year":"2012","unstructured":"Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306\u2013313 (2012).","journal-title":"Nature"},{"key":"BFnrclinonc2013158_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1172\/JCI41004","volume":"120","author":"NY Frank","year":"2010","unstructured":"Frank, N. Y., Schatton, T. & Frank, M. H. The therapeutic promise of the cancer stem cell concept. J. Clin. Invest. 120, 41\u201350 (2010).","journal-title":"J. Clin. Invest."},{"key":"BFnrclinonc2013158_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/jcp.1040830114","volume":"83","author":"V Ling","year":"1974","unstructured":"Ling, V. & Thompson, L. H. Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J. Cell Physiol. 83, 103\u2013116 (1974).","journal-title":"J. Cell Physiol."},{"key":"BFnrclinonc2013158_CR5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/0092-8674(81)90204-X","volume":"26","author":"DA Haber","year":"1981","unstructured":"Haber, D. A. & Schimke, R. T. Unstable amplification of an altered dihydrofolate reductase gene associated with double-minute chromosomes. Cell 26, 355\u2013362 (1981).","journal-title":"Cell"},{"key":"BFnrclinonc2013158_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","volume":"455","author":"RL Juliano","year":"1976","unstructured":"Juliano, R. L. & Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455, 152\u2013162 (1976).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnrclinonc2013158_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10555-012-9402-8","volume":"32","author":"M Yu","year":"2013","unstructured":"Yu, M., Ocana, A. & Tannock, I. F. Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? Cancer Metastasis Rev. 32, 211\u2013227 (2013).","journal-title":"Cancer Metastasis Rev."},{"key":"BFnrclinonc2013158_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/00062752-200401000-00006","volume":"11","author":"V Nardi","year":"2004","unstructured":"Nardi, V., Azam, M. & Daley, G. Q. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr. Opin. Hematol. 11, 35\u201343 (2004).","journal-title":"Curr. Opin. Hematol."},{"key":"BFnrclinonc2013158_CR9","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1158\/1078-0432.CCR-07-2248","volume":"14","author":"JA Engelman","year":"2008","unstructured":"Engelman, J. A. & J\u00e4nne, P. A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 14, 2895\u20132899 (2008).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2013158_CR10","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/nature09208","volume":"466","author":"Z Kan","year":"2010","unstructured":"Kan, Z. et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466, 869\u2013873 (2010).","journal-title":"Nature"},{"key":"BFnrclinonc2013158_CR11","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546\u20131558 (2013).","journal-title":"Science"},{"key":"BFnrclinonc2013158_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1023\/A:1008389706725","volume":"12","author":"S Cara","year":"2001","unstructured":"Cara, S. & Tannock, I. F. Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. Ann. Oncol. 12, 23\u201327 (2001).","journal-title":"Ann. Oncol."},{"key":"BFnrclinonc2013158_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.critrevonc.2007.04.004","volume":"64","author":"N Colombo","year":"2007","unstructured":"Colombo, N. & Gore, M. Treatment of recurrent ovarian cancer relapsing 6\u201312 months post platinum-based chemotherapy. Crit. Rev. Oncol. Hematol. 64, 129\u2013138 (2007).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"BFnrclinonc2013158_CR14","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/bjc.1998.574","volume":"78","author":"M Hejna","year":"1998","unstructured":"Hejna, M. et al. Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. Br. J. Cancer 78, 760\u2013764 (1998).","journal-title":"Br. J. Cancer"},{"issue":"Suppl.","key":"BFnrclinonc2013158_CR15","doi-asserted-by":"publisher","first-page":"259S","DOI":"10.1378\/chest.123.1_suppl.259S","volume":"123","author":"GR Simon","year":"2003","unstructured":"Simon, G. R. et al. Small cell lung cancer. Chest 123 (Suppl.), 259S\u2013271S (2003).","journal-title":"Chest"},{"key":"BFnrclinonc2013158_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1126\/science.1227670","volume":"339","author":"A Kreso","year":"2013","unstructured":"Kreso, A. et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 339, 543\u2013548 (2013).","journal-title":"Science"},{"key":"BFnrclinonc2013158_CR17","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJM200009283431302","volume":"343","author":"LB Saltz","year":"2000","unstructured":"Saltz, L. B. et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 343, 905\u2013914 (2000).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2013158_CR18","doi-asserted-by":"publisher","first-page":"5326","DOI":"10.1200\/JCO.2008.16.3212","volume":"26","author":"A Grothey","year":"2008","unstructured":"Grothey, A. et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J. Clin. Oncol. 26, 5326\u20135334 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1159\/000323491","volume":"79","author":"A Grothey","year":"2010","unstructured":"Grothey, A. Reintroduction of oxaliplatin: a viable approach to the long-term management of metastatic colorectal cancer. Oncology 79, 389\u2013399 (2010).","journal-title":"Oncology"},{"key":"BFnrclinonc2013158_CR20","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/annonc\/mdh305","volume":"15","author":"F Maindrault-G\u0153bel","year":"2004","unstructured":"Maindrault-G\u0153bel, F. et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann. Oncol. 15, 1210\u20131214 (2004).","journal-title":"Ann. Oncol."},{"key":"BFnrclinonc2013158_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.clcc.2011.06.013","volume":"11","author":"L Fornaro","year":"2012","unstructured":"Fornaro, L. et al. Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen. Clin. Colorectal Cancer 11, 71\u201376 (2012).","journal-title":"Clin. Colorectal Cancer"},{"key":"BFnrclinonc2013158_CR22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(03)12461-0","volume":"361","author":"TS Maughan","year":"2003","unstructured":"Maughan, T. S. et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 361, 457\u2013464 (2003).","journal-title":"Lancet"},{"key":"BFnrclinonc2013158_CR23","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","volume":"24","author":"C Tournigand","year":"2006","unstructured":"Tournigand, C. et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer--a GERCOR study. J. Clin. Oncol. 24, 394\u2013400 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR24","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1200\/JCO.2009.23.4344","volume":"27","author":"B Chibaudel","year":"2009","unstructured":"Chibaudel, B. et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J. Clin. Oncol. 27, 5727\u20135733 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR25","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1200\/JCO.2006.10.4380","volume":"25","author":"A de Gramont","year":"2007","unstructured":"de Gramont, A. et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J. Clin. Oncol. 25, 3224\u20133229 (2007).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl.","key":"BFnrclinonc2013158_CR26","doi-asserted-by":"crossref","first-page":"a4024","DOI":"10.1200\/jco.2009.27.15_suppl.4024","volume":"27","author":"AH de Gramont","year":"2009","unstructured":"de Gramont, A. H. et al. Definition of oxaliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin-based therapy [abstract]. J. Clin. Oncol. 27 (Suppl.), a4024 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR27","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S1470-2045(11)70102-4","volume":"12","author":"RA Adams","year":"2011","unstructured":"Adams, R. A. et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol. 12, 642\u2013653 (2011).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc2013158_CR28","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/ncponc1180","volume":"5","author":"B Seruga","year":"2008","unstructured":"Seruga, B. & Tannock, I. F. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat. Clin. Pract. Oncol. 5, 574\u2013576 (2008).","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"BFnrclinonc2013158_CR29","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/sj.bjc.6601232","volume":"89","author":"TM Beer","year":"2003","unstructured":"Beer, T. M., Garzotto, M., Henner, W. D., Eilers, K. M. & Wersinger, E. M. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br. J. Cancer 89, 968\u2013970 (2003).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc2013158_CR30","doi-asserted-by":"publisher","first-page":"E635","DOI":"10.1111\/j.1464-410X.2012.11364.x","volume":"110","author":"MM Heck","year":"2012","unstructured":"Heck, M. M. et al. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer. BJU Int. 110, E635\u2013E640 (2012).","journal-title":"BJU Int."},{"key":"BFnrclinonc2013158_CR31","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/j.1464-410X.2010.09296.x","volume":"106","author":"J Eymard","year":"2010","unstructured":"Eymard, J. et al. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int. 106, 974\u2013978 (2010).","journal-title":"BJU Int."},{"key":"BFnrclinonc2013158_CR32","first-page":"891","volume":"20","author":"J Ansari","year":"2008","unstructured":"Ansari, J. et al. Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience. Oncol. Rep. 20, 891\u2013896 (2008).","journal-title":"Oncol. Rep."},{"key":"BFnrclinonc2013158_CR33","unstructured":"Jankovic, B., Beardsley, E. & Chi, K. N. Rechallenge with docetaxel as second-line chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) after previous docetaxel: A population based analysis [abstract]. ASCO Genitourinary Cancers Symp. a196 (2008)."},{"key":"BFnrclinonc2013158_CR34","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.ejca.2010.04.010","volume":"46","author":"Y Loriot","year":"2010","unstructured":"Loriot, Y. et al. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur. J. Cancer 46, 1770\u20131772 (2010).","journal-title":"Eur. J. Cancer"},{"key":"BFnrclinonc2013158_CR35","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/cncr.23163","volume":"112","author":"TM Beer","year":"2008","unstructured":"Beer, T. M. et al. Intermittent chemotherapy in patients with metastatic androgen\u2013independent prostate cancer. Cancer 112, 326\u2013330 (2008).","journal-title":"Cancer"},{"key":"BFnrclinonc2013158_CR36","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/sj.bjc.6602198","volume":"91","author":"TM Beer","year":"2004","unstructured":"Beer, T. M., Garzotto, M., Henner, W. D., Eilers, K. M. & Wersinger, E. M. Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br. J. Cancer 91, 1425\u20131427 (2004).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc2013158_CR37","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1464-410X.2010.09498.x","volume":"107","author":"G Di Lorenzo","year":"2011","unstructured":"Di Lorenzo, G. et al. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int. 107, 234\u2013239 (2011).","journal-title":"BJU Int."},{"key":"BFnrclinonc2013158_CR38","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2010)."},{"key":"BFnrclinonc2013158_CR39","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1200\/JCO.2006.09.0183","volume":"25","author":"JY Blay","year":"2007","unstructured":"Blay, J. Y. et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J. Clin. Oncol. 25, 1107\u20131113 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR40","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1093\/annonc\/mds587","volume":"24","author":"A Patrikidou","year":"2013","unstructured":"Patrikidou, A. et al. Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. Ann. Oncol. 24, 1087\u20131093 (2013).","journal-title":"Ann. Oncol."},{"key":"BFnrclinonc2013158_CR41","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S1470-2045(10)70222-9","volume":"11","author":"A Le Cesne","year":"2010","unstructured":"Le Cesne, A. et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. 11, 942\u2013949 (2010).","journal-title":"Lancet Oncol."},{"issue":"Suppl.","key":"BFnrclinonc2013158_CR42","doi-asserted-by":"publisher","first-page":"a10032","DOI":"10.1200\/jco.2010.28.15_suppl.10032","volume":"28","author":"IL Ray-Coquard","year":"2010","unstructured":"Ray-Coquard, I. L. et al. Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: Results of the prospective BRF14 randomised phase III study comparing interruption versus continuation of IM at 5 years of treatment: a French Sarcoma Group Study [abstract]. J. Clin. Oncol. 28 (Suppl.), a10032 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0959-8049(11)70130-7","volume":"47","author":"P Reichardt","year":"2011","unstructured":"Reichardt, P. et al. Response to imatinib rechallenge of GIST that recurs following completion of adjuvant imatinib treatment\u2014the first analysis in the SSGXVIII\/AIO trial patient population [abstract 31LBA]. Eur. J. Cancer 47, 15 (2011).","journal-title":"Eur. J. Cancer"},{"key":"BFnrclinonc2013158_CR44","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"F Mahon","year":"2010","unstructured":"Mahon, F. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11, 1029\u20131035 (2010).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc2013158_CR45","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"MD Ross","year":"2013","unstructured":"Ross, M. D. et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122, 512\u2013522 (2013).","journal-title":"Blood"},{"key":"BFnrclinonc2013158_CR46","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1080\/10428190902926973","volume":"50","author":"H Goh","year":"2009","unstructured":"Goh, H. et al. Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy. Leuk. Lymphoma 50, 944\u2013951 (2009).","journal-title":"Leuk. Lymphoma"},{"key":"BFnrclinonc2013158_CR47","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s00415-009-5006-9","volume":"256","author":"A Wick","year":"2009","unstructured":"Wick, A. et al. Rechallenge with temozolomide in patients with recurrent gliomas. J. Neurol. 256, 734\u2013741 (2009).","journal-title":"J. Neurol."},{"issue":"Suppl. 2","key":"BFnrclinonc2013158_CR48","doi-asserted-by":"publisher","first-page":"S247","DOI":"10.1007\/s10072-011-0798-7","volume":"32","author":"P Gaviani","year":"2011","unstructured":"Gaviani, P. et al. Rechallenge with temozolomide in recurrent glioma. Neurol. Sci. 32 (Suppl. 2), S247\u2013S249 (2011).","journal-title":"Neurol. Sci."},{"key":"BFnrclinonc2013158_CR49","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1002\/cncr.23813","volume":"113","author":"JR Perry","year":"2008","unstructured":"Perry, J. R., Rizek, P., Cashman, R., Morrison, M. & Morrison, T. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the \u201crescue\u201d approach. Cancer 113, 2152\u20132157 (2008).","journal-title":"Cancer"},{"issue":"Suppl. 18","key":"BFnrclinonc2013158_CR50","doi-asserted-by":"crossref","first-page":"a2034","DOI":"10.1200\/jco.2007.25.18_suppl.2034","volume":"25","author":"T Jauch","year":"2007","unstructured":"Jauch, T., Hau, P. & Bogdahn, U. Re-challenge with temozolomide (TMZ) at recurrence in high-grade gliomas [abstract]. J. Clin. Oncol. 25 (Suppl. 18), a2034 (2007).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl.","key":"BFnrclinonc2013158_CR51","doi-asserted-by":"crossref","first-page":"a11514C","DOI":"10.1200\/jco.2006.24.18_suppl.11514","volume":"24","author":"C Balmaceda","year":"2006","unstructured":"Balmaceda, C. et al. Treatment with temozolomide for malignant gliomas: Is rechallenge with alternative dosing regimens successful [abstract]? J. Clin. Oncol. 24 (Suppl.), a11514C (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR52","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1002\/cncr.21564","volume":"104","author":"E Franceschi","year":"2005","unstructured":"Franceschi, E. et al. Salvage temozolomide for prior temozolomide responders. Cancer 104, 2473\u20132476 (2005).","journal-title":"Cancer"},{"key":"BFnrclinonc2013158_CR53","first-page":"1117","volume":"16","author":"DS Kong","year":"2006","unstructured":"Kong, D. S. et al. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol. Rep. 16, 1117\u20131121 (2006).","journal-title":"Oncol. Rep."},{"key":"BFnrclinonc2013158_CR54","first-page":"863","volume":"1","author":"HM Strik","year":"2008","unstructured":"Strik, H. M. et al. Rechallenge with temozolomide with different scheduling is effective in recurrent malignant gliomas. Mol. Med. Rep. 1, 863\u2013867 (2008).","journal-title":"Mol. Med. Rep."},{"key":"BFnrclinonc2013158_CR55","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1200\/JCO.2009.26.5520","volume":"28","author":"JR Perry","year":"2010","unstructured":"Perry, J. R. et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J. Clin. Oncol. 28, 2051\u20132057 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR56","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2012)."},{"key":"BFnrclinonc2013158_CR57","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.3816\/CCC.2010.n.026","volume":"9","author":"A Naing","year":"2010","unstructured":"Naing, A. & Kurzrock, R. Chemotherapy resistance and retreatment: a dogma revisited. Clin. Colorectal Cancer 9, E1\u2013E4 (2010).","journal-title":"Clin. Colorectal Cancer"},{"key":"BFnrclinonc2013158_CR58","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/annonc\/mdr623","volume":"23","author":"D Santini","year":"2012","unstructured":"Santini, D. et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann. Oncol. 23, 2313\u20132318 (2012).","journal-title":"Ann. Oncol."},{"key":"BFnrclinonc2013158_CR59","first-page":"392","volume":"24","author":"GR Oxnard","year":"2010","unstructured":"Oxnard, G. R. & Miller, V. A. Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. Oncology (Williston Park). 24, 392\u2013399 (2010).","journal-title":"Oncology (Williston Park)."},{"key":"BFnrclinonc2013158_CR60","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1093\/annonc\/mdn423","volume":"19","author":"DH Lee","year":"2008","unstructured":"Lee, D. H. et al. Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment. Ann. Oncol. 19, 2039\u20132042 (2008).","journal-title":"Ann. Oncol."},{"key":"BFnrclinonc2013158_CR61","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/annonc\/mdh006","volume":"15","author":"T Kurata","year":"2004","unstructured":"Kurata, T. et al. Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance. Ann. Oncol. 15, 173\u2013174 (2004).","journal-title":"Ann. Oncol."},{"key":"BFnrclinonc2013158_CR62","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3727\/096504005775082020","volume":"15","author":"S Yano","year":"2005","unstructured":"Yano, S. et al. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncol. Res. 15, 107\u2013111 (2005).","journal-title":"Oncol. Res."},{"key":"BFnrclinonc2013158_CR63","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1097\/JTO.0b013e318183afb0","volume":"3","author":"AS Wong","year":"2008","unstructured":"Wong, A. S., Seto, K. Y., Chin, T. M. & Soo, R. A. Lung cancer response to gefitinib, then erlotinib, then gefitinib again. J. Thorac. Oncol. 3, 1077\u20131078 (2008).","journal-title":"J. Thorac. Oncol."},{"key":"BFnrclinonc2013158_CR64","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1471-2407-7-51","volume":"7","author":"H Yokouchi","year":"2007","unstructured":"Yokouchi, H. et al. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer 7, 51 (2007).","journal-title":"BMC Cancer"},{"key":"BFnrclinonc2013158_CR65","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.lungcan.2009.06.025","volume":"68","author":"Y Tomizawa","year":"2010","unstructured":"Tomizawa, Y. et al. Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy. Lung Cancer 68, 269\u2013272 (2010).","journal-title":"Lung Cancer"},{"key":"BFnrclinonc2013158_CR66","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1159\/000326488","volume":"79","author":"H Asahina","year":"2010","unstructured":"Asahina, H. et al. Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib. Oncology 79, 423\u2013429 (2010).","journal-title":"Oncology"},{"key":"BFnrclinonc2013158_CR67","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.lungcan.2012.01.012","volume":"77","author":"IJ Oh","year":"2012","unstructured":"Oh, I. J., Ban, H. J., Kim, K. S. & Kim, Y. C. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study. Lung Cancer 77, 121\u2013127 (2012).","journal-title":"Lung Cancer"},{"key":"BFnrclinonc2013158_CR68","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1471-2407-11-90","volume":"11","author":"R Guo","year":"2011","unstructured":"Guo, R. et al. Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer. BMC Cancer 11, 90 (2011).","journal-title":"BMC Cancer"},{"key":"BFnrclinonc2013158_CR69","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1016\/j.ejca.2011.06.046","volume":"47","author":"A Becker","year":"2011","unstructured":"Becker, A. et al. Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur. J. Cancer 47, 2603\u20132606 (2011).","journal-title":"Eur. J. Cancer"},{"key":"BFnrclinonc2013158_CR70","doi-asserted-by":"publisher","first-page":"381","DOI":"10.4046\/trd.2012.72.4.381","volume":"72","author":"SJ Yoo","year":"2012","unstructured":"Yoo, S. J. et al. Second complete remission of relapsed stage IV non-small cell lung cancer following retreatment. Tuberc. Respir. Dis. (Seoul) 72, 381\u2013385 (2012).","journal-title":"Tuberc. Respir. Dis. (Seoul)"},{"issue":"Suppl. 9","key":"BFnrclinonc2013158_CR71","first-page":"a1318","volume":"23","author":"Y Namba","year":"2012","unstructured":"Namba, Y. et al. Does gefitinib re-challenge or treatment beyond progression (TBP) prolong survival of NSCLC patients? Real world evidence from gefitinib treatment responders [abstract]. Ann. Oncol. 23 (Suppl. 9), a1318 (2012).","journal-title":"Ann. Oncol."},{"issue":"Suppl.","key":"BFnrclinonc2013158_CR72","doi-asserted-by":"publisher","first-page":"a10064","DOI":"10.1200\/jco.2010.28.15_suppl.10064","volume":"28","author":"A Sawaki","year":"2010","unstructured":"Sawaki, A. et al. Impact of imatinib plus best supportive care in imatinib- and sunitinib-exposed patients with refractory advanced gastrointestinal stromal tumor [abstract]. J. Clin. Oncol. 28 (Suppl.), a10064 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR73","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1245\/s10434-011-2120-6","volume":"19","author":"A Italiano","year":"2012","unstructured":"Italiano, A. et al. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. Ann. Surg. Oncol. 19, 1551\u20131559 (2012).","journal-title":"Ann. Surg. Oncol."},{"issue":"Suppl.","key":"BFnrclinonc2013158_CR74","doi-asserted-by":"publisher","first-page":"aLBA10502","DOI":"10.1200\/jco.2013.31.18_suppl.lba10502","volume":"31","author":"YK Kang","year":"2013","unstructured":"Kang, Y. K. et al. Randomized phase III trial of imatinib (IM) rechallenge versus placebo (PL) in patients (pts) with metastatic and\/or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and sunitinib (SU): RIGHT study [abstract]. J. Clin. Oncol. 31 (Suppl.), aLBA10502 (2013).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR75","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Soft tissue sarcoma. Version 2013.1 [online] , (2013)."},{"key":"BFnrclinonc2013158_CR76","doi-asserted-by":"publisher","unstructured":"Agulnik, M. & Giel, J. L. Understanding rechallenge and resistance in the tyrosine kinase inhibitor era: imatinib in gastrointestinal stromal tumor. Am. J. Clin. Oncol. http:\/\/dx.doi.org\/10.1097\/COC.0b013e31824be3d6 .","DOI":"10.1097\/COC.0b013e31824be3d6"},{"key":"BFnrclinonc2013158_CR77","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrclinonc.2012.59","volume":"9","author":"B Escudier","year":"2012","unstructured":"Escudier, B., Szczylik, C., Porta, C. & Gore, M. Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat. Rev. Clin. Oncol. 9, 327\u2013337 (2012).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR78","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000320363","volume":"79","author":"MA W\u00f6rns","year":"2010","unstructured":"W\u00f6rns, M. A. et al. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. Oncology 79, 85\u201392 (2010).","journal-title":"Oncology"},{"key":"BFnrclinonc2013158_CR79","doi-asserted-by":"publisher","first-page":"5400","DOI":"10.1002\/cncr.25583","volume":"116","author":"IN Zama","year":"2010","unstructured":"Zama, I. N. et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 116, 5400\u20135406 (2010).","journal-title":"Cancer"},{"key":"BFnrclinonc2013158_CR80","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1159\/000328575","volume":"34","author":"V Gr\u00fcnwald","year":"2011","unstructured":"Gr\u00fcnwald, V. et al. Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC. Onkologie 34, 310\u2013314 (2011).","journal-title":"Onkologie"},{"key":"BFnrclinonc2013158_CR81","doi-asserted-by":"publisher","first-page":"E228","DOI":"10.1111\/j.1464-410X.2011.10905.x","volume":"110","author":"M Nozawa","year":"2012","unstructured":"Nozawa, M. et al. Sorafenib rechallenge in patients with metastatic renal cell carcinoma. BJU Int. 110, E228\u2013E234 (2012).","journal-title":"BJU Int."},{"issue":"Suppl.","key":"BFnrclinonc2013158_CR82","doi-asserted-by":"publisher","first-page":"e20519","DOI":"10.1200\/jco.2010.28.15_suppl.e20519","volume":"28","author":"E Fumagalli","year":"2010","unstructured":"Fumagalli, E. et al. Sunitinib rechallenge in two advanced GIST patients after third-line anti-tyrosine kinase therapy [abstract]. J. Clin. Oncol. 28 (Suppl.), e20519 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR83","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1056\/NEJMc1301237","volume":"368","author":"R Bracci","year":"2013","unstructured":"Bracci, R., Maccaroni, E. & Cascinu, S. Transient sunitinib resistance in gastrointestinal stromal tumors. N. Engl. J. Med. 368, 2042\u20132043 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2013158_CR84","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1200\/JCO.2004.06.557","volume":"22","author":"D Tripathy","year":"2004","unstructured":"Tripathy, D. et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J. Clin. Oncol. 22, 1063\u20131070 (2004).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR85","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.clbc.2012.11.008","volume":"13","author":"F Petrelli","year":"2013","unstructured":"Petrelli, F. & Barni, S. A pooled analysis of 2618 patients treated with trastuzumab beyond progression for advanced breast cancer. Clin. Breast Cancer 13, 81\u201387 (2013).","journal-title":"Clin. Breast Cancer"},{"key":"BFnrclinonc2013158_CR86","doi-asserted-by":"publisher","first-page":"R60","DOI":"10.1186\/bcr2119","volume":"10","author":"G Cancello","year":"2008","unstructured":"Cancello, G. et al. Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res. 10, R60 (2008).","journal-title":"Breast Cancer Res."},{"key":"BFnrclinonc2013158_CR87","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s10549-011-1484-4","volume":"128","author":"M Campiglio","year":"2011","unstructured":"Campiglio, M. et al. Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. Breast Cancer Res. Treat. 128, 147\u2013154 (2011).","journal-title":"Breast Cancer Res. Treat."},{"key":"BFnrclinonc2013158_CR88","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1634\/theoncologist.2009-0029","volume":"15","author":"JM Extra","year":"2010","unstructured":"Extra, J. M. et al. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist 15, 799\u2013809 (2010).","journal-title":"Oncologist"},{"key":"BFnrclinonc2013158_CR89","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.2008.19.6618","volume":"27","author":"G von Minckwitz","year":"2009","unstructured":"von Minckwitz, G. et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26\/breast international group 03\u201305 study. J. Clin. Oncol. 27, 1999\u20132006 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR90","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","volume":"28","author":"KL Blackwell","year":"2010","unstructured":"Blackwell, K. L. et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol. 28, 1124\u20131130 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR91","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1200\/JCO.2011.35.6725","volume":"30","author":"KL Blackwell","year":"2012","unstructured":"Blackwell, K. L. et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J. Clin. Oncol. 30, 2585\u20132592 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR92","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.clbc.2011.07.003","volume":"12","author":"M Pegram","year":"2012","unstructured":"Pegram, M. & Liao, J. Trastuzumab treatment in multiple lines: current data and future directions. Clin. Breast Cancer 12, 10\u201318 (2012).","journal-title":"Clin. Breast Cancer"},{"issue":"Suppl.","key":"BFnrclinonc2013158_CR93","first-page":"a4596","volume":"28","author":"AL Cohn","year":"2010","unstructured":"Cohn, A. L. et al. Clinical outcomes in bevacizumab (BV) treated patients (pts) with metastatic colorectal cancer (mCRC): results from ARIES observational cohort study (OCS) and confirmation of BRiTE data beyond progression (BBP) [abstract]. J. Clin. Oncol. 28 (Suppl.), a4596 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR94","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna, J. et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 14, 29\u201337 (2013).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc2013158_CR95","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/bjc.2012.415","volume":"107","author":"DA Reardon","year":"2012","unstructured":"Reardon, D. A. et al. Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. Br. J. Cancer 107, 1481\u20131487 (2012).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc2013158_CR96","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ygyno.2012.02.013","volume":"125","author":"PA Konstantinopoulos","year":"2012","unstructured":"Konstantinopoulos, P. A., Berlin, S. T., Campos, S. M., Matulonis, U. A. & Cannistra, S. A. Bevacizumab rechallenge after first line maintenance bevacizumab. Gynecol. Oncol. 125, 510\u2013511 (2012).","journal-title":"Gynecol. Oncol."},{"key":"BFnrclinonc2013158_CR97","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337\u2013345 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2013158_CR98","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1097\/JTO.0b013e31826913f7","volume":"7","author":"K Nishie","year":"2012","unstructured":"Nishie, K. et al. Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. J. Thorac. Oncol. 7, 1722\u20131727 (2012).","journal-title":"J. Thorac. Oncol."},{"key":"BFnrclinonc2013158_CR99","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.lungcan.2013.02.010","volume":"80","author":"M Faehling","year":"2013","unstructured":"Faehling, M. et al. EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival. Lung Cancer 80, 306\u2013312 (2013).","journal-title":"Lung Cancer"},{"key":"BFnrclinonc2013158_CR100","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2013)."},{"issue":"Suppl.","key":"BFnrclinonc2013158_CR101","doi-asserted-by":"crossref","first-page":"e15093","DOI":"10.1200\/jco.2012.30.15_suppl.e15093","volume":"30","author":"M Teo","year":"2012","unstructured":"Teo, M. & McDermott, R. S. Does RECIST-defined progression correlate with lack of further sunitinib (SU) benefit in advanced renal cell carcinoma (aRCC) [abstract]? J. Clin. Oncol. 30 (Suppl.), e15093 (2012).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl.","key":"BFnrclinonc2013158_CR102","doi-asserted-by":"publisher","first-page":"e15154","DOI":"10.1200\/jco.2011.29.15_suppl.e15154","volume":"29","author":"M Miscoria","year":"2011","unstructured":"Miscoria, M. et al. Analysis of survival after disease progression in patients with renal cell carcinoma (RCC) who failed treatment with sunitinib [abstract]. J. Clin. Oncol. 29 (Suppl.), e15154 (2011).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl.","key":"BFnrclinonc2013158_CR103","doi-asserted-by":"crossref","first-page":"a4585","DOI":"10.1200\/jco.2013.31.15_suppl.4585","volume":"31","author":"MEB Pichun","year":"2013","unstructured":"Pichun, M. E. B. et al. Continuation of sunitinib following RECIST progression on first-line sunitinib [abstract]. J. Clin. Oncol. 31 (Suppl.), a4585 (2013).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR104","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3109\/0284186X.2013.770920","volume":"52","author":"ME Revheim","year":"2013","unstructured":"Revheim, M. E. et al. Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H. Acta Oncol. 52, 776\u2013782 (2013).","journal-title":"Acta Oncol."},{"issue":"Suppl.","key":"BFnrclinonc2013158_CR105","doi-asserted-by":"crossref","first-page":"e14592","DOI":"10.1200\/jco.2013.31.15_suppl.e14592","volume":"31","author":"KB Blagoev","year":"2013","unstructured":"Blagoev, K. B. et al. Relationship of the emergence of KRAS mutations and resistance to panitumumab in second-line treatment of colorectal cancer (CRC) [abstract]. J. Clin. Oncol. 31 (Suppl.), e14592 (2013).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR106","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl Cancer Inst. 92, 205\u2013216 (2000).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc2013158_CR107","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"BFnrclinonc2013158_CR108","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","volume":"25","author":"H Choi","year":"2007","unstructured":"Choi, H. et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J. Clin. Oncol. 25, 1753\u20131759 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR109","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher, H. I. et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26, 1148\u20131159 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR110","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl, R. L., Jacene, H., Kasamon, Y. & Lodge, M. A. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 50, 122S\u2013150S (2009).","journal-title":"J. Nucl. Med."},{"key":"BFnrclinonc2013158_CR111","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412\u20137420 (2009).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2013158_CR112","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni, R. & Llovet, J. M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 30, 52\u201360 (2010).","journal-title":"Semin. Liver Dis."},{"key":"BFnrclinonc2013158_CR113","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/nrc1650","volume":"5","author":"JJ Kim","year":"2005","unstructured":"Kim, J. J. & Tannock, I. F. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat. Rev. Cancer 5, 516\u2013525 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrclinonc2013158_CR114","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/jnci\/djn088","volume":"100","author":"S Leyvraz","year":"2008","unstructured":"Leyvraz, S. et al. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial. J. Natl Cancer Inst. 100, 533\u2013541 (2008).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc2013158_CR115","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1200\/JCO.2011.40.6405","volume":"30","author":"LN Shulman","year":"2012","unstructured":"Shulman, L. N. et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J. Clin. Oncol. 30, 4071\u20134076 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR116","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1200\/JCO.2010.31.5374","volume":"29","author":"A Gennari","year":"2011","unstructured":"Gennari, A. et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J. Clin. Oncol. 29, 2144\u20132149 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR117","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1038\/sj.onc.1202526","volume":"18","author":"M Pegram","year":"1999","unstructured":"Pegram, M. et al. Inhibitory effects of combinations of HER-2\/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18, 2241\u20132251 (1999).","journal-title":"Oncogene"},{"key":"BFnrclinonc2013158_CR118","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1158\/0008-5472.CAN-05-1182","volume":"66","author":"GE Konecny","year":"2006","unstructured":"Konecny, G. E. et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 66, 1630\u20131639 (2006).","journal-title":"Cancer Res."},{"key":"BFnrclinonc2013158_CR119","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1200\/JCO.2003.11.126","volume":"21","author":"ML Rothenberg","year":"2003","unstructured":"Rothenberg, M. L. et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J. Clin. Oncol. 21, 2059\u20132069 (2003).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR120","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1200\/JCO.2003.03.074","volume":"21","author":"I Chau","year":"2003","unstructured":"Chau, I. & Cunningham, D. Oxaliplatin for colorectal cancer in the United States: better late than never. J. Clin. Oncol. 21, 2049\u20132051 (2003).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR121","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/030089169207800102","volume":"29","author":"R Supino","year":"1992","unstructured":"Supino, R., Rodolfo, M., Mariani, M. & Mapelli, E. Heterogeneity and phenotypic instability of chemotherapeutic and immunologic sensitivity in murine and human melanoma cell clones. Tumori 29, 5\u20139 (1992).","journal-title":"Tumori"},{"key":"BFnrclinonc2013158_CR122","first-page":"1148","volume":"49","author":"PJ Ferguson","year":"1989","unstructured":"Ferguson, P. J. & Cheng, Y. C. Phenotypic instability of drug sensitivity in a human colon carcinoma cell line. Cancer Res. 49, 1148\u20131153 (1989).","journal-title":"Cancer Res."},{"key":"BFnrclinonc2013158_CR123","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1126\/science.1160165","volume":"322","author":"AA Cohen","year":"2008","unstructured":"Cohen, A. A. et al. Dynamic proteomics of individual cancer cells in response to a drug. Science 322, 1511\u20131516 (2008).","journal-title":"Science"},{"key":"BFnrclinonc2013158_CR124","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1097\/01.cad.0000136879.96680.bc","volume":"15","author":"J Deschatrette","year":"2004","unstructured":"Deschatrette, J. et al. Telomere dynamics determine episodes of anticancer drug resistance in rat hepatoma cells. Anticancer Drugs 15, 671\u2013678 (2004).","journal-title":"Anticancer Drugs"},{"key":"BFnrclinonc2013158_CR125","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ccr.2010.10.012","volume":"18","author":"E Quintana","year":"2010","unstructured":"Quintana, E. et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18, 510\u2013523 (2010).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc2013158_CR126","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1002\/stem.1257","volume":"30","author":"S Kobayashi","year":"2012","unstructured":"Kobayashi, S. et al. LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution. Stem Cells 30, 2631\u20132644 (2012).","journal-title":"Stem Cells"},{"key":"BFnrclinonc2013158_CR127","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69\u201380 (2010).","journal-title":"Cell"},{"key":"BFnrclinonc2013158_CR128","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1158\/1535-7163.MCT-10-1120","volume":"10","author":"K He","year":"2011","unstructured":"He, K., Xu, T. & Goldkorn, A. Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype. Mol. Cancer Ther. 10, 938\u2013948 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"BFnrclinonc2013158_CR129","doi-asserted-by":"publisher","first-page":"e25351","DOI":"10.1371\/journal.pone.0025351","volume":"6","author":"E Weisberg","year":"2011","unstructured":"Weisberg, E. et al. Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PLoS ONE 6, e25351 (2011).","journal-title":"PLoS ONE"},{"key":"BFnrclinonc2013158_CR130","first-page":"1780","volume":"47","author":"JG Zijlstra","year":"1987","unstructured":"Zijlstra, J. G., de Vries, E. G. & Mulder, N. H. Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 47, 1780\u20131784 (1987).","journal-title":"Cancer Res."},{"key":"BFnrclinonc2013158_CR131","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1126\/science.2108497","volume":"247","author":"BA Teicher","year":"1990","unstructured":"Teicher, B. A. et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247, 1457\u20131461 (1990).","journal-title":"Science"},{"key":"BFnrclinonc2013158_CR132","doi-asserted-by":"publisher","first-page":"90ra59","DOI":"10.1126\/scitranslmed.3002356","volume":"3","author":"J Chmielecki","year":"2011","unstructured":"Chmielecki, J. et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci. Transl. Med. 3, 90ra59 (2011).","journal-title":"Sci. Transl. Med."},{"key":"BFnrclinonc2013158_CR133","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1158\/1535-7163.MCT-08-0759","volume":"8","author":"C Morales","year":"2009","unstructured":"Morales, C. et al. Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells. Mol. Cancer Ther. 8, 424\u2013432 (2009).","journal-title":"Mol. Cancer Ther."},{"key":"BFnrclinonc2013158_CR134","doi-asserted-by":"publisher","first-page":"e19144","DOI":"10.1371\/journal.pone.0019144","volume":"6","author":"L Zhang","year":"2011","unstructured":"Zhang, L. et al. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS ONE 6, e19144 (2011).","journal-title":"PLoS ONE"},{"key":"BFnrclinonc2013158_CR135","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1158\/1535-7163.MCT-09-1106","volume":"9","author":"HJ Hammers","year":"2010","unstructured":"Hammers, H. J. et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol. Cancer Ther. 9, 1525\u20131535 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"BFnrclinonc2013158_CR136","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1593\/neo.10804","volume":"12","author":"TC Tang","year":"2010","unstructured":"Tang, T. C. et al. Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia 12, 928\u2013940 (2010).","journal-title":"Neoplasia"},{"key":"BFnrclinonc2013158_CR137","doi-asserted-by":"publisher","first-page":"4518","DOI":"10.1158\/0008-5472.CAN-07-5999","volume":"68","author":"GJ Sabnis","year":"2008","unstructured":"Sabnis, G. J., Macedo, L. F., Goloubeva, O., Schayowitz, A. & Brodie, A. M. Stopping treatment can reverse acquired resistance to letrozole. Cancer Res. 68, 4518\u20134524 (2008).","journal-title":"Cancer Res."},{"key":"BFnrclinonc2013158_CR138","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2012)."},{"key":"BFnrclinonc2013158_CR139","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/1479-5876-9-220","volume":"9","author":"X Wang","year":"2011","unstructured":"Wang, X. et al. High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma. J. Transl. Med. 9, 220 (2011).","journal-title":"J. Transl. Med."},{"key":"BFnrclinonc2013158_CR140","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1158\/1078-0432.CCR-04-1347","volume":"11","author":"DB Solit","year":"2005","unstructured":"Solit, D. B. et al. Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin. Cancer Res. 11, 1983\u20131989 (2005).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2013158_CR141","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1158\/1078-0432.CCR-10-1905","volume":"17","author":"MF Rimawi","year":"2011","unstructured":"Rimawi, M. F. et al. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2\/neu-overexpressing breast tumor xenografts. Clin. Cancer Res. 17, 1351\u20131361 (2011).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2013158_CR142","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature11814","volume":"494","author":"M Das Thakur","year":"2013","unstructured":"Das Thakur, M. et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494, 251\u2013255 (2013).","journal-title":"Nature"},{"key":"BFnrclinonc2013158_CR143","doi-asserted-by":"publisher","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"LV Sequist","year":"2011","unstructured":"Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).","journal-title":"Sci. Transl. Med."},{"key":"BFnrclinonc2013158_CR144","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1097\/JTO.0b013e318282e047","volume":"8","author":"A Hata","year":"2013","unstructured":"Hata, A., Katakami, N., Kaji, R., Fujita, S. & Imai, Y. Does T790M disappear? Successful gefitinib rechallenge after T790M disappearance in a patient with EGFR-mutant non-small-cell lung cancer. J. Thorac. Oncol. 8, e27\u2013e29 (2013).","journal-title":"J. Thorac. Oncol."},{"key":"BFnrclinonc2013158_CR145","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/bjc.1986.166","volume":"54","author":"F Formelli","year":"1986","unstructured":"Formelli, F., Rossi, C., Supino, R. & Parmiani, G. In vivo characterization of a doxorubicin resistant B16 melanoma cell line. Br. J. Cancer 54, 223\u2013233 (1986).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc2013158_CR146","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/bjh.12198","volume":"160","author":"MT Petrucci","year":"2013","unstructured":"Petrucci, M. T. et al. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br. J. Haematol. 160, 649\u2013659 (2013).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc2013158_CR147","doi-asserted-by":"crossref","first-page":"a4714","DOI":"10.1182\/blood.V110.11.4714.4714","volume":"110","author":"M Fiegl","year":"2007","unstructured":"Fiegl, M. et al. Retreatment with alemtuzumab after a first, successful alemtuzumab treatment in B-CLL [abstract]. Blood 110, a4714 (2007).","journal-title":"Blood"},{"key":"BFnrclinonc2013158_CR148","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1159\/000322866","volume":"79","author":"I Hrusovsky","year":"2010","unstructured":"Hrusovsky, I. et al. Bortezomib retreatment in relapsed multiple myeloma\u2014results from a retrospective multicentre survey in Germany and Switzerland. Oncology 79, 247\u2013254 (2010).","journal-title":"Oncology"},{"key":"BFnrclinonc2013158_CR149","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/sj.bjc.6604051","volume":"98","author":"J Shamash","year":"2008","unstructured":"Shamash, J. et al. A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer. Br. J. Cancer 98, 22\u201324 (2008).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc2013158_CR150","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrclinonc.2010.122","volume":"7","author":"C Palmieri","year":"2010","unstructured":"Palmieri, C. et al. Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nat. Rev. Clin. Oncol. 7, 561\u2013574 (2010).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR151","first-page":"w13562","volume":"142","author":"C Taverna","year":"2012","unstructured":"Taverna, C., Voegeli, J., Trojan, A., Olie, R. A. & von Rohr, A. Effective response with bortezomib retreatment in relapsed multiple myeloma\u2014a multicentre retrospective survey in Switzerland. Swiss Med. Wkly 142, w13562 (2012).","journal-title":"Swiss Med. Wkly"},{"key":"BFnrclinonc2013158_CR152","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00277-011-1192-5","volume":"90","author":"M Fiegl","year":"2011","unstructured":"Fiegl, M. et al. Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients. Ann. Hematol. 90, 1083\u20131091 (2011).","journal-title":"Ann. Hematol."},{"key":"BFnrclinonc2013158_CR153","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/0140-6736(92)92353-H","volume":"340","author":"P Sonneveld","year":"1992","unstructured":"Sonneveld, P. et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet 340, 255\u2013259 (1992).","journal-title":"Lancet"},{"key":"BFnrclinonc2013158_CR154","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1200\/JCO.1991.9.1.17","volume":"9","author":"TP Miller","year":"1991","unstructured":"Miller, T. P. et al. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J. Clin. Oncol. 9, 17\u201324 (1991).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR155","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1046\/j.1365-2141.2001.03171.x","volume":"115","author":"P Sonneveld","year":"2001","unstructured":"Sonneveld, P. et al. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). Br. J. Haematol. 115, 895\u2013902 (2001).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc2013158_CR156","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/1097-0142(19950201)75:3<815::AID-CNCR2820750311>3.0.CO;2-R","volume":"75","author":"WS Dalton","year":"1995","unstructured":"Dalton, W. S. et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer 75, 815\u2013820 (1995).","journal-title":"Cancer"},{"key":"BFnrclinonc2013158_CR157","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1056\/NEJMsb1013826","volume":"364","author":"TJ Smith","year":"2011","unstructured":"Smith, T. J. & Hillner, B. E. Bending the cost curve in cancer care. N. Engl. J. Med. 364, 2060\u20132065 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2013158_CR158","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1093\/jnci\/djp177","volume":"101","author":"T Fojo","year":"2009","unstructured":"Fojo, T. & Grady, C. How much is life worth: cetuximab, non\u2013small cell lung cancer, and the $440 billion question. J. Natl Cancer Inst. 101, 1044\u20131048 (2009).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc2013158_CR159","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1056\/NEJM199111073251904","volume":"325","author":"HB Muss","year":"1991","unstructured":"Muss, H. B. et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N. Engl. J. Med. 325, 1342\u20131348 (1991).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2013158_CR160","doi-asserted-by":"crossref","unstructured":"[No authors listed] Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. J. Clin. Oncol. 18, 3115\u20133124 (2000).","DOI":"10.1200\/JCO.2000.18.17.3115"},{"key":"BFnrclinonc2013158_CR161","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1158\/0008-5472.CAN-12-4183","volume":"73","author":"E Guerin","year":"2013","unstructured":"Guerin, E., Man, S., Xu, P. & Kerbel, R. S. A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Cancer Res. 73, 2743\u20132748 (2013).","journal-title":"Cancer Res."},{"key":"BFnrclinonc2013158_CR162","doi-asserted-by":"publisher","first-page":"137ra75","DOI":"10.1126\/scitranslmed.3003643","volume":"4","author":"S Sivanand","year":"2012","unstructured":"Sivanand, S. et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci. Transl. Med. 4, 137ra75 (2012).","journal-title":"Sci. Transl. Med."},{"key":"BFnrclinonc2013158_CR163","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1158\/1535-7163.MCT-09-0960","volume":"9","author":"K Hashimoto","year":"2010","unstructured":"Hashimoto, K. et al. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol. Cancer Ther. 9, 996\u20131006 (2010).","journal-title":"Mol. Cancer Ther."},{"issue":"Suppl.","key":"BFnrclinonc2013158_CR164","doi-asserted-by":"crossref","first-page":"a3502","DOI":"10.1200\/jco.2013.31.15_suppl.3502","volume":"31","author":"M Koopman","year":"2013","unstructured":"Koopman, M. et al. Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): the phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG) [abstract]. J. Clin. Oncol. 31 (Suppl.), a3502 (2013).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR165","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000108592","volume":"71","author":"S Pignata","year":"2006","unstructured":"Pignata, S. et al. Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study. Oncology 71, 320\u2013326 (2006).","journal-title":"Oncology"},{"key":"BFnrclinonc2013158_CR166","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/S0140-6736(73)91672-3","volume":"1","author":"RC Young","year":"1973","unstructured":"Young, R. C., Chabner, B. A., Canellos, G. P., Schein, P. S. & DeVita, V. T. Maintenance chemotherapy for advanced Hodgkin's disease in remission. Lancet 1, 1339\u20131343 (1973).","journal-title":"Lancet"},{"key":"BFnrclinonc2013158_CR167","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood.V51.6.1005.1005","volume":"51","author":"R Alexanian","year":"1978","unstructured":"Alexanian, R., Gehan, E., Haut, A., Saiki, J. & Weick, J. Unmaintained remissions in multiple myeloma. Blood 51, 1005\u20131011 (1978).","journal-title":"Blood"},{"key":"BFnrclinonc2013158_CR168","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1200\/JCO.1987.5.10.1556","volume":"5","author":"HB Muss","year":"1987","unstructured":"Muss, H. B., Smith, L. R. & Cooper, M. R. Tamoxifen rechallenge: response to tamoxifen following relapse after adjuvant chemohormonal therapy for breast cancer. J. Clin. Oncol. 5, 1556\u20131558 (1987).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013158_CR169","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/sj.bjc.6604052","volume":"98","author":"RA Cox","year":"2008","unstructured":"Cox, R. A. & Sundar, S. Re-induction of hormone sensitivity to diethylstilboestrol in androgen refractory prostate cancer patients following chemotherapy. Br. J. Cancer 98, 238\u2013239 (2008).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc2013158_CR170","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1002\/1097-0142(19861201)58:11<2546::AID-CNCR2820581131>3.0.CO;2-N","volume":"58","author":"LH Klotz","year":"1986","unstructured":"Klotz, L. H., Herr, H. W., Morse, M. J. & Whitmore, W. F. Jr. Intermittent endocrine therapy for advanced prostate cancer. Cancer 58, 2546\u20132550 (1986).","journal-title":"Cancer"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2013.158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2013.158","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2013.158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:22:37Z","timestamp":1684466557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2013.158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,3]]},"references-count":170,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["BFnrclinonc2013158"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2013.158","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,3]]}}}